Building No. 1
4-5th Floor 16 North Hongda Road Beijing Economic-Technological Dev. Area
Beijing
China
https://www.acotec.cn
Settore/i: Healthcare
Settore: Medical Devices
Impiegati a tempo pieno: 638
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Ms. Jing Li | Executive Chairperson of the Board & CEO | 4,05M | N/D | 1973 |
Mr. Silvio Rudolf Schaffner | COO & Executive Director | 2,48M | N/D | 1970 |
Dr. Ulrich Reinhold Speck | Chief Technology Officer | N/D | N/D | 1942 |
Mr. Chen Li | Joint Company Secretary | N/D | N/D | 1990 |
Ms. Ching Yi Li | Joint Company Secretary | N/D | N/D | N/D |
Acotec Scientific Holdings Limited operates as an interventional medical device company that offers vascular interventional treatment products in Mainland China, Europe, and internationally. The company's products include AcoArt Orchid & Dhalia, a paclitaxel DCB used to prevent stenosis or occlusion in superficial femoral artery (SFA) and popliteal artery (PPA) for the treatment of lower extremity artery disease (LEAD) with a vascular interventional approach; and AcoArt Tulip & Litos, a paclitaxel coated DCB used to prevent stenosis or occlusion in below-theknee (BTK) arteries for the treatment of chronic limb-threatening ischemia with a vascular interventional approach. It also offers devices targeting vascular surgery, including AcoArt Iris & Jasmin; AcoArt Lily & Rosmarin; Peripheral Aspiration System (AcoStream); Radiofrequency Ablation System (AcoArt Cedar); Peripheral Support Catheter (Vericor); The PTA Balloon (P-Conic); and 2nd Gen Peripheral Aspiration System (2nd Generation AcoStream). In addition, its devices targeting cardiology include Semi-compliant PTCA Balloon (YAN), Coronary CTO Recanalization Balloon (RT-Zero), and Coronary CTO Antegrade Micro-Catheter (Vericor-14); devices targeting nephrology include Paclitaxel Coated High-Pressure Balloon (ACOART AVENS) and AV Scoring Balloon (Peridge); devices targeting neurology comprise Intracranial PTA Balloon (NEO-Skater); and devices targeting andrology include AcoArt Orchid & Dhalia and AcoArt Tulip & Litos. Further, the company trades procedural medical devices. The company was incorporated in 2020 and is headquartered in Beijing, China. Acotec Scientific Holdings Limited operates as a subsidiary of Boston Scientific Group plc.
L'ISS Governance QualityScore di Acotec Scientific Holdings Limited al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.